AstraZeneca(US:AZN) Di Yi Cai Jing·2026-02-25 06:43Group 1: Executive Compensation - AstraZeneca's CEO Pascal Soriot will receive a total compensation of £17.7 million (approximately 164 million RMB) in 2025, making him one of the highest-paid executives in the FTSE 100 index [1] - Novartis CEO Vas Narasimhan's compensation for 2025 is set at 24.9 million Swiss francs (approximately 220 million RMB), reflecting a 30% increase from 2024, marking a new high since he took office in 2018 [1] - Roche CEO Thomas Schinecker will receive a total compensation of 10.2 million Swiss francs (approximately 9.075 million RMB) in 2025 [2] - Sanofi's CEO Paul Hudson's total compensation for 2025 is reported to be €10.9 million (approximately 88.37 million RMB) [2] Group 2: Company Performance and Stock Returns - AstraZeneca's strong performance and stock price have contributed to Soriot's annual bonus of up to £4.3 million, a 22% increase from 2024 [1] - Novartis's long-term incentive plan has a payout rate of 188% for the period from 2023 to 2025, valued at 17.3 million Swiss francs, with the company's stock price rising from about $90 at the end of 2022 to nearly $160 by early 2026, resulting in a total shareholder return of 84% [1] - Novo Nordisk faced challenges in the past year, with new CEO Maziar Mike Doustdar receiving 20.7 million Danish kroner (approximately 2.25 million RMB) during his initial months, while former CEO Lars Fruergaard Jorgensen received nearly $20 million (approximately 137 million RMB) in 2025, including severance and compensation [2] Group 3: Comparison with U.S. Pharmaceutical Executives - U.S. pharmaceutical executives' salaries for 2025 have not yet been disclosed, but historically, they tend to be higher than their European counterparts [3] - In 2024, Eli Lilly's CEO David Ricks had a salary of $29.2 million (approximately 200 million RMB), ranking first among global pharmaceutical CEOs, while Pfizer's CEO Albert Bourla earned $24.6 million (approximately 170 million RMB), ranking second [3]